GT Medical Technologies

What GT Medical Technologies does

GT Medical Technologies, Inc. is a Tempe, Arizona-based, privately held medical device company founded in 2017 by a group of brain tumor specialists (David G. Brachman, Heyoung McBride, Peter Nakaji, Emad Youssef, Theresa Thomas) to address the treatment gap between brain tumor resection surgery and post-operative external beam radiation. The company's sole commercial product, GammaTile, is an FDA-cleared, bioresorbable collagen tile embedded with four cesium-131 radiation seeds offset 3mm from the tile surface; the implant is placed at the time of craniotomy and delivers approximately 88-90% of its therapeutic dose within 30 days, eliminating the typical 2-8 week wait between surgery and adjuvant radiation. GammaTile is cleared for both newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms and is supported by a peer-reviewed evidence base that includes the ROADS Phase 3 randomized trial (presented at ASCO 2026 with superior local control and survival outcomes versus standard stereotactic radiotherapy), the GESTALT and BRIDGES glioblastoma trials, and a real-world registry study reporting 92.3% local control at 12 months and a 9.8% Grade 3 toxicity rate with no radiation necrosis.

GT Medical operates an enterprise direct-sales model, selling GammaTile through a proprietary ordering portal (orders.gammatile.com) and field representatives to hospitals and cancer centers across the United States. Revenue is one-time per procedure on a quote-based pricing model, with a formal Commitment Pledge that waives charges for recurrent-tumor cases canceled intraoperatively if pathology reveals only necrotic tissue. The company has built a network of 20+ Centers of Excellence anchored by MD Anderson, Memorial Sloan Kettering, USC Brain Tumor Center, AdventHealth Orlando, Piedmont Atlanta, Miami Cancer Institute, VCU Massey and Mayfield Brain and Spine, complemented by a full suite of medical physics and reimbursement toolkits (Cavity Surface Area Calculator, Medical Physics Toolkit, RAM License Toolkit, Coding and Reimbursement Toolkit).

The company has raised approximately $263 million in equity across nine rounds (most recently a $100 million Series E in June 2026 led by Viking Global Investors) plus a $35 million debt facility from Horizon Technology Finance in 2024, and it acquired IsoRay and its Cesium-131 isotope business in December 2023 to vertically integrate its radioactive source supply chain. Leadership comprises an experienced medtech executive bench (CEO Per Langoe, CMO Michael Garcia, CSO/CFO James Leech, COO Ole Mikkelsen, CMO Richard Low, CCO Jeff Lewis) and operates a 101-250 person organization from its Tempe headquarters.

Name

GT Medical Technologies

Legal name

GT Medical Technologies, Inc.

Website

https://gammatile.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable collagen implant embedded with cesium-131 radiation seeds for targeted brain tumor radiation therapy at the time of resection. The company sells directly to U.S. hospitals and cancer centers.

Ownership category

akta.pro rank

Product category

Radiation Therapy Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Irradiation Apparatus Manufacturing (334517), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Brain tumor treatment
• Radiation therapy devices
• Brachytherapy implants
• Neurosurgical medical devices
• Collagen tile implants

Headquarters

HQ city

Tempe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. GammaTile Device Sales: GT Medical Technologies generates revenue through the sale of GammaTile radiation therapy devices to hospitals and treatment centers. The company sells directly to healthcare providers who order tiles through the GammaTile ordering portal for use during brain tumor resection surgeries. Revenue is one-time per procedure, with unused tiles eligible for return.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

GT Medical Technologies manufactures and sells GammaTile, an FDA-cleared bioresorbable collagen tile embedded with four cesium-131 radiation seeds, implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy to the tumor cavity. The company supports hospitals and cancer centers with ordering infrastructure, medical physics tools, coding and reimbursement resources, Centers of Excellence program, and clinical trial participation.

Product overview

GT Medical Technologies offers GammaTile, a tile-based radiation therapy (TBRT) system consisting of the FDA-cleared GammaTile bioresorbable collagen implant embedded with cesium-131 radiation seeds, along with supporting medical physics tools (Cavity Surface Area Calculator, Lookup Table, Medical Physics Toolkit, RAM License Toolkit), clinical programs (ROADS Phase 3 trial, GESTALT trial, GammaTile Registry), and commercial services (Coding and Reimbursement Toolkit, Commitment Pledge, Centers of Excellence program). The core GammaTile product is implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• GammaTile FDA-cleared bioresorbable collagen tile embedded with cesium-131 radiation seeds, implanted at the time of brain tumor resection surgery to deliver immediate, targeted radiation therapy to remaining tumor cells. Designed for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms, including glioblastoma, brain metastases, and meningiomas.
• GammaTile Commitment Pledge Product policy and risk-sharing service for healthcare providers that waives the GammaTile charge when procedures are canceled because intraoperative pathology shows only necrotic tissue, reducing financial exposure for hospitals performing recurrent brain tumor resections.
• ROADS Phase 3 Clinical Trial (NCT04365374) Sponsored randomized Phase 3 clinical trial comparing GammaTile plus resection versus resection plus post-operative stereotactic radiotherapy for newly diagnosed brain metastases. Generates clinical evidence supporting adoption and is offered through participating medical centers including MD Anderson.
• GammaTile Centers of Excellence Program Designated network of medical institutions recognized for exceptional expertise in GammaTile procedures, offering proctoring support, patient education, and clinical outcomes research. Includes MD Anderson, USC Brain Tumor Center, AdventHealth Orlando, Piedmont, Mayfield Brain & Spine, Miami Cancer Institute, and VCU Massey Cancer Center.

Quantifiable outcome

• 92.3% local tumor control at 12 months in newly diagnosed brain metastases patients
• +5 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 21 October 2025Lead institution for the ROADS (Radiation Options After Deduced Surgery) Phase 3 randomized clinical trial comparing GammaTile to standard stereotactic radiotherapy for newly diagnosed brain metastases. Dr. Weinberg presented final results at ASCO 2026.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 21 October 2025Sponsor and lead institution for the Phase II randomized clinical trial studying intracavity carrier-embedded Cs-131 brachytherapy for recurrent brain metastases. The trial compares GammaTile plus surgery versus surgery alone.
• Various Medical Institutions (Centers of Excellence)coreStrategic or Co-development PartnerNetwork of 20+ GammaTile Centers of Excellence including USC Brain Tumor Center, AdventHealth Orlando, Piedmont, Mayfield Brain & Spine, Miami Cancer Institute, and others. These institutions demonstrate exceptional expertise in GammaTile procedures and contribute to patient education and clinical outcomes research.
• Finn PartnersminorGTM or Marketing PartnerPublic relations firm handling media inquiries for GammaTile and the ROADS clinical trial. Contact: [email protected]

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IBA (Ion Beam Applications): Proton therapy equipment manufacturer and radioisotope producer; competes with GammaTile in brain tumor radiation oncology and shares exposure to the radioisotope supply chain through its radiopharmaceuticals business.
• Elekta: Global leader in radiation therapy and radiosurgery hardware (including Leksell Gamma Knife) widely used for brain tumor treatment; competes with GammaTile in the post-operative brain metastases setting where Elekta's linear accelerator-based systems and Gamma Knife remain the standard of care compared against GammaTile in the ROADS trial.
• Varian Medical Systems (Siemens Healthineers): Dominant external beam radiation therapy and stereotactic radiosurgery platform provider (TrueBeam, Edge); competes with GammaTile for brain tumor treatment dollars and serves the same radiation oncology departments targeted by GT Medical's field sales force.
• BTG (Boston Scientific): Through its BTG acquisition, Boston Scientific markets a portfolio of brachytherapy seeds (including I-125-based systems historically used in brain tumors); competes with GammaTile's Cs-131 brachytherapy approach and shares the implantable radiation oncology category.
• Accuray: Maker of CyberKnife and TomoTherapy stereotactic radiosurgery systems used for brain metastases and other intracranial indications; competes against GammaTile in the post-operative radiation setting referenced in the ROADS trial comparator arm.

Direct peers

• Novocure: Commercial-stage oncology company with Optune (TTFields), an FDA-approved therapy for newly diagnosed and recurrent glioblastoma; directly competes with GammaTile in the recurrent glioblastoma indication and addresses the same neuro-oncology patient population.
• IsoRay Medical: Historical direct competitor and brachytherapy isotope producer using Cesium-131 seeds; GT Medical acquired IsoRay in December 2023 to vertically integrate the Cs-131 supply chain that powers GammaTile, making IsoRay now an in-house asset rather than an independent competitor.
• Theragenics: Specialized brachytherapy seed manufacturer with a portfolio that has historically included brain tumor applications; competes directly with GammaTile in implantable radioactive seed therapy and shares the same clinical and regulatory pathway.

Emerging players

• ViewRay: MR-guided radiation therapy systems used in oncology, including intracranial applications; represents an emerging technology alternative to both traditional external beam radiation and implantable brachytherapy approaches for brain tumors.

Regional players

• Mevion Medical Systems: Compact proton therapy system manufacturer; competes with GammaTile as an alternative radiation modality for intracranial and pediatric brain tumors, primarily in academic and specialty oncology centers in North America.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GammaTile
• YouTubeyoutube.com/@GammaTile
• Facebookfacebook.com/GammaTile
• LinkedInlinkedin.com/company/gt-medical-technologies-inc
• Instagraminstagram.com/gammatile

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GT Medical Technologies